Gastrointestinal effects are experienced by a significant proportion of patients, particularly during dose initiation and escalation: Nausea (affecting up to 20% of patients) is typically most pronounced in the first few weeks and often diminishes with continued use [10] [11] Diarrhoea or constipation may occur as the digestive system adjusts to slower gastric emptying Abdominal discomfort, bloating, or indigestion are common but usually mild Vomiting occurs less frequently but may necessitate dose adjustment These gastrointestinal symptoms can be minimised by eating smaller, more frequent meals, avoiding high-fat foods, and ensuring adequate hydration
Theres no shame in saying I have high blood pressure or I inherited this condition from my family, Jones said
Verified compounds ship with their specific Janoshik COA, batch number matched to the vial label and verifiable against our public lab results archive
Endocrinology 1996
By combining GLP-1, GIP, and glucagon receptor activity, these therapies may enhance appetite suppression, improve insulin sensitivity, and increase energy expenditure
